Oruka Therapeutics (NASDAQ:ORKA) Issues Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) announced its earnings results on Monday. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04), FiscalAI reports.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA opened at $98.82 on Monday. The stock has a market cap of $5.96 billion, a PE ratio of -50.94 and a beta of -0.34. The company’s fifty day moving average is $82.59 and its 200 day moving average is $60.25. Oruka Therapeutics has a 52 week low of $12.84 and a 52 week high of $100.34.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, April 30th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a “buy” rating in a research report on Monday, April 27th. Barclays upped their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Finally, Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares in the company, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the sale, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. This trade represents a 19.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 188,406 shares of company stock valued at $12,019,683. Corporate insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the stock. Viking Global Investors LP purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $51,280,000. Deep Track Capital LP raised its holdings in Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after buying an additional 735,983 shares during the last quarter. RTW Investments LP raised its holdings in Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after buying an additional 112,499 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in Oruka Therapeutics during the 4th quarter valued at $51,840,000. Finally, Remedium Capital Partners LLC purchased a new stake in Oruka Therapeutics during the 4th quarter valued at $47,054,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.